Mo Chen

Mo Chen

Taithera, Inc.

2016-2017

Technologies

Therapeutic

Indication

Musculoskeletal Disorders

Oncology

Orphan Diseases

Executive Summary

View/Download

Taithera is a revolutionary nanomedicine bone-targeted drug delivery and controlled release platform technology for the treatment of musculoskeletal conditions focused initially on fracture healing & bone cancer (osteosarcoma is our first oncology target).

Newsletter Signup

Corporate Supporters